Kamil Pohlodek, Edita Dobáková, Petra Scholtzová, Michaela Bártová, Anna Stecová
The authors present in this pilot study their first experience with the evaluation of the extracellular domain (ECD) of the human epidermal growth factor receptor-2 (HER2) in serum in breast cancer patients by an automated immunochemical method. In a prospective clinical study they are evaluating 30 women. The results of serum HER2 assay are compared with the results from tissue HER2 evaluation from surgical specimens. The authors correlate the results also with some basic clinicopathological prognostic and predictive parameters. In the discussion they consider the possible role of serum ECD HER2 levels in treatment decision making or as a predictor of the disease relapse.